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Protocol
AbstrACt
Introduction Tobacco is the world’s leading preventable 
cause of disease and death. People with depression 
are twice as likely to smoke and are less responsive 
to standard tobacco treatments as compared with 
the general population. A Cochrane systematic review 
of randomised controlled trials of smoking cessation 
treatment for smokers with current or historical depression 
found that adding mood management to usual smoking 
treatment improved quit rates. However, the review did not 
examine if variation in intervention delivery or intervention 
functions impacted on treatment effectiveness. With 
the aim of providing information to develop tailored 
approaches to treating smoking for people with current 
depression, we will add-on to the Cochrane review in three 
ways: (1) use the Template for Intervention Description 
and Replication checklist to determine if variations in 
mood management delivery have impact on intervention 
effectiveness, (2) use the Taxonomy of Behaviour Change 
techniques for smoking cessation to examine which 
behaviour change functions are most effective for smoking 
cessation in people with current depression and  
(3) examine the difference in change in depression scores 
between intervention and control arms.
Methods and analysis We will include randomised 
controlled trials of smokers with current depression as 
identified by a previous Cochrane review and the in-
progress update of this Cochrane review. We will use 
meta-regression to examine (1) if variations in delivery 
of mood management impact on smoking cessation 
intervention effectiveness, (2) determine which behaviour 
change functions are most effective for smoking cessation 
and (3) use meta-analysis of the difference in change in 
depression scores between treatment arms from baseline 
to follow-up to determine if offering smoking cessation 
treatment causes psychological harm.
Ethics and dissemination Ethical approval is not 
required for this study. We will disseminate the findings of 
this work at national and international conferences, and to 
relevant patient panels.
PrOsPErO registration number CRD42017070741.
bACkgrOund
Tobacco is the world’s leading preventable 
cause of disease and death.1 In the UK and 
in other developed nations, smoking prev-
alence has declined substantially in the 
general population, but has remained largely 
unchanged in those with mental health 
problems resulting in an excess burden of 
smoking-related mortality in this group.2 3 
People with depression are twice as likely to 
smoke4 5 and are less responsive to standard 
tobacco treatments than are the general 
population6 7 leading to urgent calls for 
targeted smoking interventions.8 
The Cochrane group conducted a system-
atic review and meta-analysis of smoking 
cessation interventions for smokers with past 
or present depression. The review included 
pharmacological and behavioural interven-
tions to aid cessation and found that adding 
mood management to a usual smoking treat-
ment (eg, nicotine replacement therapy, 
telephone counselling and self-help website) 
moderately increased smoking cessation 
rates in people with current depression 
compared with usual smoking treatment 
strengths and limitations of this study
 ► We will examine the impact of variation in intervention 
delivery and intervention functions on treatment 
effectiveness using peer-reviewed checklists: The 
Behaviour Change Taxonomy and Template for 
Intervention Description and Replication.
 ► We will obtain an estimate of the effect of stopping 
smoking on depression symptoms.
 ► The study design may suffer from low power and/or 
publication bias.
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alone, reporting a risk ratio (RR) of 1.47 (95% CI 1.13 to 
1.92).9 The review highlighted the importance of adding 
psychological techniques to handle depressive symptoms 
in standard smoking treatments for people with depres-
sion. However, in the meta-analysis, there was variation 
between the included studies’ direction of effect and it is 
possible that this variation may be in part related to differ-
ences in intervention delivery or intervention functions, 
for example. Further investigation into these potential 
modifiers will provide useful information for develop-
ment of smoking cessation interventions for people with 
current depression.9
In addition, the review did not examine the impact of 
behavioural or psychological smoking cessation inter-
ventions on depression symptoms. This is an important 
question as many clinicians believe that smoking may 
offer mental health benefits, or that their patients’ mental 
health may deteriorate on cessation.10 However, there 
are data from meta-analyses of cohort studies indicating 
that quitting smoking may improve depression,11 but due 
to common pitfalls of observational data one cannot be 
sure that this is a causal association. If treating smoking is 
found to not worsen depression, then these data can be 
used to assure clinicians that they are not causing psycho-
logical harm by helping their patients to quit smoking.
In our review, we aim to add-on to the 2013 Cochrane 
review9 in three ways. We will:
1. use the Template for Intervention Description and 
Replication (TIDieR) checklist12 to determine if varia-
tions in mood management delivery impact on inter-
vention effectiveness in people with depression;
2. use the Taxonomy of Behaviour Change (BCT) 
techniques for smoking cessation13 to examine which 
behaviour change functions are most effective for 
smoking cessation in people with current depression;
3. examine the difference in change in depression scores 
between intervention and control arms in people with 
current depression.
MEthOds
The study protocol has been registered in advance on 
the International Prospective Register of Systematic 
Reviews ((PROSPERO); ID: CRD42017070741; http://
www. crd. york. ac. uk/ PROSPERO/). All methods and 
study reporting will adhere to guidance described within 
the Cochrane Handbook for Systematic Reviews and 
Meta-analyses of Randomised Controlled Trials.14
search strategy
We will include relevant studies identified by a previ-
ously conducted Cochrane review of smoking cessation 
interventions for people with depression, and from 
the Cochrane review update due to commence this 
year.9 Studies have been identified from the Cochrane 
Central Register of Controlled trials (CENTRAL), 
MEDLINE, EMBASE and PsycINFO using search terms 
related to ‘depression’, and ‘tobacco’ or ‘smoking’ as 
recommended by the Tobacco Addiction Group and the 
Cochrane Depression, Anxiety and Neurosis Group. See 
the Tobacco Addiction Group Module in The Cochrane 
Library for full search strategies and the list of other 
resources searched.9 This search strategy will be updated 
for additional relevant studies published from 2013. RVM 
is the lead author for the Cochrane review published in 
2013, and will lead on the Cochrane update of this review. 
To avoid duplicating efforts across teams and given the 
high reliance of Cochrane methods, RVM will share the 
eligible studies prior to data extraction of the Cochrane 
update. We predict that this will take place in early 2018.
Inclusion criteria
Inclusion criteria are based on those outlined in the 2013 
Cochrane review.9
 ► study design: randomised controlled trials only;
 ► participants: daily smokers with current depression, 
any definition of depression, no restrictions by phys-
ical or mental comorbidities;
 ► intervention: any smoking cessation intervention;
 ► intervention delivery: self-help, individual, group, 
internet;
 ► control: any (eg, including self-help, no treatment, 
etc);
 ► outcome: any ascertainment of smoking cessation;
 ► follow-up: follow-up at a minimum of 6 months from 
the quit date.
Outcomes
 ► Smoking status at final follow-up (the same as the 
2013 Cochrane review9).
 ► Change in depression scores from baseline to final 
follow-up (not reported in the 2013 Cochrane 
review9).
data extraction
We will use the following data as reported in the 2013 
Cochrane review9:
 ► Trial methods: study design, setting, country, 
randomisation methods.
 ► Participants: number of participants per interven-
tion group, definition of depression, type of smoker, 
comorbid conditions, age, sex, ethnicity, level of 
education, nicotine dependence, mean/median 
number of cigarettes per day, depression type and 
severity.
 ► Outcomes: smoking cessation status, biochemical 
validation, depression scores, length of follow-up.
 ► Measures of treatment effect, smoking cessation 
(study aims 1 and 2): We will use the following 
outcome data as reported in the Cochrane review. 
The number of participants randomised to the inter-
vention and control groups, and the number of 
participants who quit smoking in the intervention 
and control groups.14
We will extract the following additional data not 
reported in the 2013 Cochrane review9:
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 ► Interventions: the number of and function of behav-
iour change techniques used (ie, where sufficient 
details are not reported in text, we will attempt to 
obtain intervention protocols), and the presence or 
absence of TIDieR checklist items.
 ► Control: the number of and function of behaviour 
change techniques used (ie, where sufficient details 
are not reported in text, we will attempt to obtain 
intervention protocols), and the presence or absence 
of TIDieR checklist items.
 ► Measures of treatment effect, depression symptoms 
(study aim 3): for each trial arm, we will obtain mean 
depression scores and measure of variance at base-
line and follow-up, mean differences and measures 
of variance from baseline to follow-up or differences 
in change between trial arms’ scores from baseline to 
follow-up and measures of variance.
Coding of tIdier checklist
The 2013 Cochrane review9 did not extract any informa-
tion relevant to the TIDieR checklist12; these data are new 
to this review.
For study aim 1, we will use the TIDieR checklist12 to 
determine if variations in mood management delivery 
impact on intervention effectiveness. We will use a modi-
fied version of TIDieR as not all items on the checklist are 
useful in the context of this study (table 1) (eg, ‘Describe 
any rationale, theory or goal of the elements essential to 
the intervention’). Coding will be conducted separately 
by two researchers to confirm agreement.
Coding of behaviour change intervention functions using the 
bCt
The 2013 Cochrane review9 did not extract any infor-
mation relevant to the BCT13; these data are new to this 
review.
For study aim 2, we will code the number of behaviour 
change techniques, categorise the behaviour change 
techniques according to their function and record 
whether the function was either absent or present during 
intervention delivery13 (table 2). Coding will be conducted 
separately by two researchers to confirm agreement.
Measures of treatment effect
 ► Smoking cessation (study aims 1 and 2): We will 
present treatment effects as RRs and 95% CIs.14 RRs 
will be calculated as follows: (number of participants 
who quit smoking in the intervention group/number 
of participants randomised to intervention group) 
divided by (number of participants who quit smoking 
in control group/number of participants randomised 
to the control group).
Table 1 Modified version of Template for Intervention Description and Replication (TIDieR) checklist12 for use in meta-
regression analysis*
Item Categories
Materials for mood management (ie, physical or informational materials used) Paper-based information, 
website, homework, diary, audio 
information, etc
Procedures for mood management: activities, procedures or activities used in the 
intervention to support activities
Relaxation techniques, mood 
monitoring, etc
Did the participant see the same intervention provider for all mood management sessions? Yes, no
Mood management provider Nurse, psychologist, 
General Practitioner, counsellor, 
etc
Training given to intervention provider? Yes, no
Level of education of intervention provider BSc, MSc, PhD
Mode of mood management delivery Individual, group
Location of mood management intervention Hospital, participant’s home, 
General Practitioner surgery, 
university, etc
Number of mood management sessions Continuous variable
Length of mood management session (minutes) Continuous variable
Was the mood management intervention tailored to participant? Yes, no
Number of mood management sessions tailored to participant? Continuous variable
Was participant adherence to mood management intervention measured? Yes, no
Did participants adhere to the mood management intervention? Yes, no or %
Was therapist adherence to mood management intervention measured? Yes, no
Did therapists adhere to mood management programme? Yes, no or %
*The categories are likely to be further developed during data extraction to include new items.
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 ► Difference in change in depression scores between 
trial arms (study aim 3): We will present the standard-
ised mean difference (SMD), and 95% CIs of change 
in depression scores between treatment arms, from 
baseline to follow-up.
Analysis
We will conduct analyses using Stata V.14 or Revman 
software, and use the following analytical procedures to 
address each study aim:
1. Do variations mood management delivery impact 
on intervention effectiveness? If there are sufficient 
data, we will conduct random effects metaregres-
sion models using the metareg command15 in which 
modified TIDieR checklist items (see table 1) will be 
regressed on the study’s effect estimate. First, univari-
ate analyses will be conducted to determine the asso-
ciation between each item and the study effect size. 
Subsequently, items with the strongest association will 
be added to the metaregression model first, and all 
other variables will be added in turn regardless of sig-
nificance in the univariate model.
2. Which behaviour change functions are most ef-
fective for smoking cessation in people with 
current depression? If there are sufficient data, we 
will conduct random effects meta-regression models 
using the metareg command15 in which behaviour 
change functions (see table 2) will be regressed on the 
study’s effect estimate. First, univariate analyses will 
be conducted to determine the association between 
each intervention function and the study effect size. 
Subsequently, variables with the strongest association 
will be added to the meta-regression model first, and 
all other variables will be added in turn regardless of 
significance in the univariate model.
3. What is the difference in change in depression scores 
between intervention and control arms? If there are 
sufficient data, we will use a generic inverse variance 
random effects model to pool the SMD of change 
in depression scores in treatment and control arms, 
from baseline to follow-up. We will use a random ef-
fects model as it incorporates heterogeneity both 
within and between studies.
Statistical heterogeneity: We will quantify statistical 
heterogeneity using I2 which describes the percentage 
(%) of between-study variability due to heterogeneity 
rather than chance; values over 50% suggest substantial 
heterogeneity, and values over 75% suggest considerable 
heterogeneity.14 Tau2 will be used to test whether differ-
ences between studies’ effect estimates are compatible 
with chance alone.16
Sensitivity and subgroup analyses: We will conduct 
sensitivity analyses to examine if the following study 
characteristics influence the meta-analysis results: study 
quality (as measured by Cochrane’s Risk of Bias tool), 
loss-to-follow-up and severity of depression.
Assessment of publication bias: We will examine funnel 
plots for evidence of asymmetry and conduct egger 
tests for evidence of small study bias using the metabias 
command.15
Ethics and dissemination
Ethical approval is not required for the conduct of this 
systematic review and meta-analysis. We will disseminate 
the findings of this work at international and national 
conferences, and to the UK Centre for Tobacco and 
Alcohol Studies Smokers’ Panel.
dIsCussIOn
We will use the methods described in this protocol 
to determine: (1) if variations in delivery of mood 
management impact on smoking cessation intervention 
effectiveness in people with depression, (2) to examine 
which behaviour change functions are most effective 
for smoking cessation in people with depression and 
(3) examine the difference in change in depression 
scores between intervention and control arms.
We hold no strong hypotheses about which variations in 
mood management delivery/behaviour change functions 
will impact on treatment effectiveness. Potentially, inter-
vention functions that focus on improving motivation to 
quit may strengthen the association between intervention 
and smoking cessation, as poor motivation is a hallmark 
symptom of depression. We do predict that at minimum 
smoking cessation intervention will not be associated with 
a worsening in depression, and that intervention may be 
associated with an improvement in depression scores 
when compared with control.11
Table 2 Example of behaviour change functions and techniques13
Behaviour change function Examples of technique
Specific focus on behaviour and addressing motivation Provide information on consequences of smoking and smoking 
cessation
Boost motivation and self-efficacy
Provide feedback on current behaviour
Specific focus on behaviour and maximising self-
regulatory capacity/skills
Advise on changing routine
Advise on environmental restructuring
Set graded tasks
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Clinical applications
If we can show that certain variations in delivery of mood 
management or behavioural support for smoking cessa-
tion are associated with higher abstinence rates, these 
data can be used by clinicians and researchers to optimise 
smoking cessation programmes for people with depres-
sion. Second, data pertaining to the impact of helping 
smokers with depression to quit smoking on depression 
symptoms will be imperative to smokers and clinicians.
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